SUMMARY
Schizophrenia is associated with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling. The metabotropic glutamate receptor subtype 5 (mGlu 5 ) is a closely associated signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathology of schizophrenia. Efficacy of mGlu 5 positive allosteric modulators (PAMs) in animal models of psychosis and cognition was previously attributed to potentiation of NMDAR function. To directly test this hypothesis, we identified VU0409551 as a novel mGlu 5 PAM that exhibits distinct stimulus bias and selectively potentiates mGlu 5 coupling to G aq -mediated signaling but not mGlu 5 modulation of NMDAR currents or NMDAR-dependent synaptic plasticity in the rat hippocampus. Interestingly, VU0409551 produced robust antipsychotic-like and cognitionenhancing activity in animal models. These data provide surprising new mechanistic insights into the actions of mGlu 5 PAMs and suggest that modulation of NMDAR currents is not critical for in vivo efficacy.
INTRODUCTION
Multiple clinical and genetic studies have led to the hypothesis that hypofunction of the N-methyl-D-aspartate subtype of glutamate receptor (NMDAR) plays an important role in the pathophysiology of schizophrenia and that administration of agents that enhance NMDAR function can provide symptomatic improvement in schizophrenic patients (Coyle et al., 2012; Field et al., 2011; Timms et al., 2013) . Based on these findings, multiple efforts have focused on developing approaches to enhance NMDAR signaling as a potential novel treatment strategy for schizophrenia. Metabotropic glutamate receptor subtype 5 (mGlu 5 ) is a closely associated signaling partner with the NMDAR and activation of mGlu 5 potentiates NMDAR responses and NMDAR-mediated synaptic plasticity in forebrain regions implicated in the pathology of schizophrenia (Ayala et al., 2009; Collingridge et al., 1983; Doherty et al., 1997; Homayoun et al., 2004; Mannaioni et al., 2001; Marino and Conn, 2002) . Consistent with this, deletion or blockade of mGlu 5 exacerbates psychotomimetic-like and cognition-disrupting effects of NMDAR antagonists (Brody et al., 2004; Campbell et al., 2004; Henry et al., 2002; Kinney et al., 2003) , and highly selective mGlu 5 positive allosteric modulators (PAMs) potentiate mGlu 5 -mediated regulation of NMDAR currents and have cognition-enhancing and antipsychotic-like effects in preclinical models (Ayala et al., 2009; Darrah et al., 2008; Gastambide et al., 2013; Gregory et al., 2013a; Kinney et al., 2005; Liu et al., 2008; Noetzel et al., 2012; Parmentier-Batteur et al., 2014; Rodriguez et al., 2010) . However, activation of mGlu 5 has multiple actions in forebrain circuits and the hypothesis that mGlu 5 -induced potentiation of NMDAR currents is required for in vivo efficacy of mGlu 5 PAMs has not been directly tested.
The majority of actions of mGlu 5 are mediated by activation of the G aq GTP-binding protein subunit , whereas mGlu 5 -induced potentiation of NMDAR currents in forebrain neurons is mediated by interactions of mGlu 5 with NMDARs through adaptor proteins that are independent of signaling through G aq (Gao et al., 2013; Hu et al., 2012; Park et al., 2013; Shepherd and Huganir, 2007) . We now report discovery and characterization of a novel mGlu 5 PAM, VU0409551, that induces a robust potentiation of mGlu 5 coupling to G aq -mediated calcium mobilization and other signaling pathways but does not enhance mGlu 5 modulation of NMDAR currents in hippocampal neurons. In addition, VU0409551 potentiates NMDAR-independent long-term depression (LTD) but does not potentiate NMDAR-dependent long-term potentiation (LTP) in the rat hippocampus. Interestingly, VU0409551 produces robust, dose-dependent efficacy in preclinical rodent models of psychosis and cognitive function. These studies challenge the prevailing hypothesis that the in vivo effects of mGlu 5 PAMs in models related to schizophrenia and cognitive function are mediated by potentiation of mGlu 5 modulation of NMDAR currents and provide important new insights into modulation for specific effects of mGlu 5 activation.
RESULTS

VU0409551
Is a Potent, Highly Selective Potentiator of mGlu 5 We have identified multiple mGlu receptor PAMs, including PAMs that display striking stimulus bias and selectively potentiate coupling of mGlu receptors to specific signaling pathways (Hammond et al., 2010; Noetzel et al., 2013; Sheffler and Conn, 2008; Zhang et al., 2005) . Based on these studies, we initiated an effort to optimize novel mGlu 5 PAMs that potentiate mGlu 5 -mediated G aq signaling and calcium mobilization but do not potentiate coupling of mGlu 5 to modulation of NMDAR currents and possess physicochemical and pharmacokinetic properties suitable for systemic dosing, a characteristic not achieved with previous biased mGlu 5 PAMs. This culminated in the discovery of VU0409551 as a potent mGlu 5 PAM ( Figure S1 ). VU0409551 behaved as a classic mGlu 5 PAM (Conn et al., 2014) in rat mGlu 5 -expressing HEK293A cells and did not possess intrinsic agonist activity ( Figure 1A ) but potentiated the response to an EC 20 concentration of glutamate with an EC 50 of 235 nM ( Figure 1B ). Increasing concentrations of VU0409551 resulted in progressive leftward shifts in the glutamate concentration-response curve with a maximum fold shift of 11 at a 30 mM concentration of VU0409551 ( Figure 1C ). VU0409551 (10 mM) is highly selective for mGlu 5 and had no effect at the other mGlu receptor subtypes ( Figure 1D ). Additionally, radioligand competition binding assays revealed that VU0409551 (10 mM) displays weak affinity for a 2A adrenergic receptors (IC 50 8.9 mM) but has no activity at any of 66 other receptors and ion channels (Table S1 ). These studies indicate that VU0409551 is a potent and highly selective pure PAM of mGlu 5 -mediated calcium mobilization.
VU0409551-Induced ERK Phosphorylation
VU0409551 also potentiated glutamate-induced phosphorylation of extracellular signal-regulated kinase 1/2 (pERK1/2) in mGlu 5 -expressing cells ( Figure 1E ). In addition, VU0409551 increased pERK1/2 in the absence of added glutamate. This is similar to effects of other mGlu 5 PAMs, which can also display agonist activity in this assay with greater efficacy than glutamate (Gregory et al., 2012 (Gregory et al., , 2013b . Analysis of these data with an operational model of allosterism (Gregory et al., 2012) allowed for quantification of VU0409551 agonist efficacy (t B : 1.04), affinity (K B : 89 nM), and cooperativity (b: 1.43) with glutamate.
VU0409551-Induced Modulation of mGlu 5 in Native Systems
We next assessed the ability of VU0409551 to potentiate mGlu 5 signaling in CNS preparations. Similar to its effects in HEK293A-mGlu 5 cells, VU0409551 had no intrinsic agonist activity in cultured rat cortical astrocytes (Peavy et al., 2002) but potentiated glutamate-induced calcium mobilization in these cells (EC 50 = 317 ± 1 nM; Figure 1F ). This effect was blocked by the mGlu 5 negative allosteric modulator (NAM) MPEP (10 mM; Figure 1F) . Activation of mGlu 5 also plays an important role in induction of an NMDAR-independent form of long-term depression (LTD) at the hippocampal Schaffer collateral-CA1 (SC-CA1) synapse (Huber et al., 2001; Rammes et al., 2003) . To assess the effect of VU0409551 on LTD induced by the group I mGlu receptor agonist, DHPG, we recorded field excitatory postsynaptic potentials (fEPSPs) from the dendritic layer of CA1 after stimulation of the Schaffer collaterals ( Figure 2 ). In agreement with our previous studies , DHPG (75 mM) induced robust LTD at the hippocampal SC-CA1 synapse measured 55 min after washout of DHPG ( Figure 2B ; 54.9% ± 5.3% of baseline fEPSP slope), whereas a lower concentration of DHPG (25 mM) induced only slight depression of fEPSPs (Figure 2B ; 78.9% ± 5.7% of baseline fEPSP slope). As observed previously with other mGlu 5 PAMs (Ayala et al., 2009; Noetzel et al., 2012 Noetzel et al., , 2013 , VU0409551 potentiated the response to 25 mM DHPG, inducing robust LTD ( Figure 2B ; 43.7% ± 4.6% baseline). Although VU0409551 alone induced a slight depression in the fEPSP slope, this effect was transient and returned to baseline within 10 min of washout ( Figure S2 ). Taken together, these data suggest that VU0409551 potentiates multiple responses to mGlu 5 activation in recombinant and native systems.
VU0409551 Does Not Potentiate mGlu 5 Modulation of NMDAR Currents in CA1 Pyramidal Cells Activation of mGlu 5 potentiates NMDAR currents in multiple cell types, including hippocampal CA1 pyramidal cells (Awad et al., 2000; Doherty et al., 1997; Fitzjohn et al., 1996; Mannaioni et al., 2001; O'Brien et al., 2004) . Consistent with previous studies, whole-cell patch-clamp recordings from CA1 pyramidal cells revealed that DHPG induced a concentration-dependent increase in inward currents evoked by application of NMDA through a patch pipette positioned adjacent to the recorded cell ( Figures 3A-3C and 3F) . Application of the recently reported mGlu 5 PAM 5PAM523 (Parmentier-Batteur et al., 2014) had no effect on NMDA-evoked currents when added alone but potentiated the effect of 3 mM DHPG on NMDAR currents ( Figures 3D  and 3F ). Likewise, structurally distinct mGlu 5 PAMs, VU0422465 , ADX47273 (Liu et al., 2008) , and VU0092273 , resulted in a similar potentiation of DHPGinduced modulation of NMDAR currents ( Figure 3F ). In contrast, VU0409551 had no effect on NMDAR currents either alone or in the presence of 3 mM DHPG (Figures 3E and 3F) . Consistent with these results, current-clamp studies showed VU0409551 had no effect on NMDA-evoked responses when applied alone ( Figures S3B-S3D ) and did not potentiate 3 mM DHPG-induced depolarization or increase in NMDAR response ( Figures S3A-S3D ). We also assessed the effect of VU0409551 on NMDAR-mediated fEPSPs at the SC-CA1 synapse and found that VU0409551 had no effect on the NMDAR-fEPSP slope (Figures S3F and S3G) . Finally, voltage-clamp recordings revealed that VU0409551 (10 mM) had no effects on the EPSC NMDA /EPSC AMPA ratio when applied alone ( Figures 3G-3J ) and did not have effects on 3 mM DHPG-induced inhibition of EPSC AMPA or the DHPG-induced slight increase in the EPSC NMDA /EPSC AMPA ratio ( Figures 3G-3J ). Taken together, these results indicate that VU0409551 represents a unique molecular probe and behaves as an mGlu 5 PAM, potentiating multiple responses to mGlu 5 activation in HEK293A-mGlu 5 cells, astrocytes, and hippocampal slices but does not potentiate mGlu 5 -mediated increases in NMDAR currents.
VU0409551 Does Not Potentiate LTP at the SC-CA1 Synapse Previous studies reveal that mGlu 5 PAMs enhance theta burst stimulation (TBS)-induced LTP at the SC-CA1 synapse and this effect has been postulated to be mediated by potentiation of (E) VU0409551 potentiates glutamate-stimulated ERK1/2 phosphorylation and exhibits robust agonist activity in this assay. (F) VU0409551 potentiates glutamate-induced calcium mobilization in rat cortical astrocytes with a potency of 317 nM and maximum glutamate response of 79.5%, which is blocked by addition of 10 mM of the mGlu 5 antagonist MPEP. Data represent mean ± SEM from two to four independent experiments performed in duplicate or triplicate.
mGlu 5 -induced modulation of NMDAR currents (Ayala et al., 2009; Noetzel et al., 2013) . To determine the effects of VU0409551 on induction of LTP, we initiated maximal LTP using a standard TBS protocol (saturation TBS; four trains of 10 Hz TBS), which resulted in a 141.1% ± 8.4% increase in fEPSP slope, compared with baseline, when measured 35 min after stimulation (Figures 4A and 4B) . In contrast, a single train of lower-frequency bursts resulted in a slight potentiation of the fEPSP slope (Figures 4A and 4B; 116 .2% ± 3.3% of baseline) and was used as a threshold protocol for induction of TBS LTP. Consistent with previous reports (Ayala et al., 2009; Noetzel et al., 2013) , pretreatment of slices with the mGlu 5 PAM VU0092273 resulted in a significant potentiation of the fEPSP slope in response to threshold TBS ( Figure 4B ). In contrast, treatment of hippocampal slices with VU0409551 followed by threshold TBS had no effect on fEPSP slope, compared with threshold TBS alone ( Figure 4B ; 110.4% ± 4.0% of baseline). Similar to the LTD studies, a slight decrease in the fEPSP slope observed following application of VU0409551 resolved within 25 min of application, which is before LTP quantification (Figure S2 ). The ability of VU0409551 to potentiate NMDARindependent mGlu-LTD but not NMDAR-dependent LTP is consistent with the lack of effect of this mGlu 5 PAM on modulation of NMDAR currents.
Rat Pharmacokinetics and Brain Distribution of VU0409551 Before using this compound for in vivo studies, we evaluated the pharmacokinetic (PK) profile and brain distribution of VU0409551 after systemic administration. VU0409551 exhibited a moderate clearance from plasma (CL p ; 33 ml/min/kg) with a large volume of distribution at steady-state (V ss ; 9.6 l/kg) and a moderate half-life (t 1/2 ; 3.9 hr) following a single intravenous (i.v.) administration in rats (2.5 mg/kg bodyweight, Figure S4 ). VU0409551 biotransformation experiments in rat hepatocytes revealed moderate turnover through multiple oxidative pathways with mono-hydroxylation of the phenyl ring (para-position) producing the predominant metabolite, which was inactive at mGlu 5 in in vitro assays (data not shown). A single oral (per os [p.o.]) administration (3 mg/kg) of VU0409551 revealed high oral bioavailability (%F = 63), a maximum concentration in plasma (C max,p ) of 270 nM, a time to reach maximum concentration in plasma (T max,p ) of 1.3 hr, and an area-under-the-curve from 0-last (AUC 0-last ) of 2.9 mM*hr ( Figure S5 ). The in vitro fraction of unbound VU0409551 in rat plasma (fu p ) of 0.07 and in rat brain (fu br ) of 0.04 suggested a brain to plasma partition coefficient (K p ) at unrestricted equilibrium ([fu p ]/[fu br ]) of 1.8 (Table  S2) . Distribution of VU0409551 to brain in vivo at 1.5 hr following a single p.o. administration (3, 10, 30, and 100 mg/kg) revealed a brain to plasma K p of 2.3 and corresponding unbound brain to plasma K p (K p,uu ) of 1.3, suggesting the compound freely permeates the blood-brain barrier (BBB), and unbound concentrations in brain and plasma reach unrestricted equilibrium (Table S2) . Thus, VU0409551 exhibits excellent PK and brain exposure for use in in vivo studies.
VU0409551 Induces Wake-Promoting Effects in Rats
Previous studies reveal that mGlu 5 PAMs increase wakefulness in rodents Parmentier-Batteur et al., 2012) and this provides an excellent measure of their in vivo CNS activity. Acute oral administration of VU0409551 exerts clear central activity immediately following administration, as expressed by a dose-dependent decrease in sleep. Specifically, VU0409551 dose-dependently decreased the total time spent asleep, leading to significant reduction in non-rapid eye movement (NREM) and REM sleep ( Figure 5) . A 10 mg/kg dose had a modest effect on vigilance states, decreasing time asleep for 2 hr post-administration. A dose of 60 mg/kg VU0409551 significantly decreased the total time spent in NREM and REM sleep for up to 7 hr post-administration ( Figure 5 ).
Antipsychotic-like and Procognitive Efficacy of VU0409551
Discovery and optimization of VU0409551 as an mGlu 5 PAM that has an excellent PK profile and does not potentiate coupling of mGlu 5 to NMDAR currents provides an unprecedented opportunity to directly assess the importance of potentiation of NMDAR signaling in antipsychotic-like and cognition-enhancing effects of mGlu 5 PAMs in rodent models. Two primary models used to assess antipsychotic-like activity of mGlu 5 PAMs include reversal of NMDAR antagonist-or amphetamine-induced hyperlocomotion (AHL) and reversal of pharmacologically induced disruptions in prepulse inhibition (PPI) of the acoustic startle reflex. Interestingly, pretreatment (30 min) of rats with VU0409551 (10-100 mg/kg) reversed the increased locomotor activity induced by the NMDAR antagonist MK-801 (0.2 mg/kg, subcutaneous [s.c.], Figure 6A ). The minimal effective dose (MED) of VU0409551 was 10 mg/kg with a maximum reversal of 49.7% EPSCs NMDA at holding potentials of -60 mV and +40 mV in controls, during application of 3 mM DHPG, 10 mM VU0409551, or co-application of VU0409551 and DHPG, respectively. Traces in right panels in (G) and (H) are scaled to the peak of AMPAR-EPSCs and superimposed, demonstrating that VU0409551 did not potentiate the EPSC NMDA /EPSC AMPA ratio when applied alone or co-applied with DHPG. (I and J) Summary of the effects of 3 mM DHPG, 10 mM VU0409551, and 10 mM VU0409551 along with 3 mM DHPG on EPSC AMPA amplitude and the EPSC NMDA /EPSC AMPA ratio, respectively (n = 4-6). Data represent mean ± SEM, *p < 0.05, **p < 0.005.
at the highest dose ( Figure 6A ). In addition, pretreatment (30 min) with VU0409551 (3-100 mg/kg) dose-dependent reversed increased locomotor activity induced by administration of amphetamine (1 mg/kg, s.c.) with an MED of 3 mg/kg, an ED 50 of 5.9 mg/kg, and a maximum reversal of 78.1% ( Figures S6A  and S6B ). VU0409551 terminal (1.5 hr) unbound brain concentration data from rat AHL studies were used to determine an in vivo EC 50 using individual animal concentration-efficacy data from all dose groups. This analysis provided an EC 50 of 97 nM with an E max of 82% for reversal of AHL. Additionally, reversal of AHL by VU0409551 was blocked by the mGlu 5 antagonist, MTEP, supporting mGlu 5 -mediated antipsychotic-like efficacy (data not shown). Finally, pretreatment (30 min) with VU0409551 (56.6 and 100 mg/kg) reversed amphetamine-induced disruptions in PPI in rats ( Figure S6C ).
In addition to its antipsychotic-like activity, VU0409551 demonstrated robust cognition enhancement. VU0409551 induced a dose-dependent enhancement of contextual fear conditioning acquisition in rats. Pretreatment (30 min) with VU0409551 (0.3-10 mg/kg) prior to conditioning significantly enhanced acquisition of fear memory assessed 24 hr later ( Figure 6B ), demonstrating efficacy of this novel mGlu 5 PAM in enhancing an established form of hippocampal-dependent cognitive function. Moreover, administration of VU0409551 (1-10 mg/kg) 30 min prior to exposure to two identical objects resulted in a dose-dependent increase in recognition memory in the novel object recognition task, another commonly used rodent learning and memory paradigm dependent upon hippocampal function ( Figure 6C ). To evaluate the effects of VU0409551 on working memory and executive function, we used the operant delayed non-matching to position (DNMTP) task. Pretreatment (60 min) with VU0409551 (10-60 mg/kg) prior to the testing session increased the proportion of correct responses at a 10 and 20 s delay (60 mg/kg; Figure 6D ) with no change in total number of trials initiated ( Figure S6D ). Based on the PK analysis, the doses of VU0409551 required to elicit antipsychotic-like and cognition-enhancing effects provide brain concentrations that fit well with those required to potentiate mGlu 5 -mediated responses in cell lines and in brain slices (100 nM-30 mM). These data demonstrate that VU0409551 has robust efficacy in rodent models used to predict antipsychoticlike and cognition-enhancing effects that are similar to that described for previous mGlu 5 PAMs that potentiate mGlu 5 modulation of NMDAR currents. A) VU0409551 does not potentiate NMDAR-mediated, theta burst stimulation-induced long-term potentiation (LTP). Saturation TBS resulted in a significant increase in fEPSP slope 35 min after stimulation. Threshold TBS resulted in a small increase in fEPSP slope measured 35 min after stimulation. Bath application of 10 mM VU0409551 for 20 min, followed by threshold TBS, resulted in no change in fEPSP slope from threshold TBS alone. In contrast, bath application of 1 mM VU0092273 for 20 min, followed by threshold TBS, resulted in a significant enhancement of fEPSP slope measured 35 min after stimulation. Inset shows representative fEPSP traces for each condition for baseline (black trace) and 35 min after TBS (gray trace). (B) Quantification of the change in fEPSP slope measured 35 min after TBS stimulation. In contrast to VU0092273, bath application of VU0409551 for 20 min followed by threshold TBS did not result in significant LTP 35 min after stimulation (p = 0.0002, n = 6-11). Data represent mean ± SEM. **p < 0.01, when compared with threshold TBS.
Similar to previous reports with 5PAM523 (Parmentier-Batteur et al., 2014), we found that VU0424465 induced cell death, as assessed by the number of FJC-positive neurons in the auditory cortex and adjacent cortical regions 24 hr following a single relatively low dose (3 mg/kg, intraperitoneal [i.p], Figures 7A and 7B ). In contrast, daily administration of a high dose of VU0409551 (120 mg/kg, p.o.) for 4 consecutive days did not induce in FJC staining in sections harvested from rats 24 hr following the last dose ( Figures 7A and 7B) .
In order to determine the PK of VU0409551 following repeat (once daily for 4 days) administration (120 mg/kg, p.o., 75% PEG 400 in water) used in FJC studies, a satellite PK study was performed using an identical design; plasma concentrations were obtained at 3, 7, and 24 hr post-administration on day 1 and day 4 ( Figure S7 ). In this study, VU0409551 displayed similar, high C max,p and exposure on day 1 (C max,p , 7.0 mM; AUC 0-last , 96 mM*hr) and day 4 (C max,p , 7.5 mM; AUC 0-last , 95 mM*hr). Thus, the exposure was maintained at levels far in excess of those required to achieve maximal efficacy over this 4-day dosing period.
Finally, consistent with previous reports (Parmentier-Batteur et al., 2014; Rook et al., 2013) , VU0424465 and 5PAM523 induced behavioral convulsions in rats that could be assessed using the Racine scale of behavioral convulsions ( Figure 7C ). In contrast VU0409551, at doses up to 100 times that required for measureable efficacy in behavioral models (120 mg/kg), did not induce behavioral convulsions in rats ( Figure 7C ). In addition, while chronic administration of previous mGlu 5 PAMs, such as 5PAM523, led to progressive worsening of seizure activity (Parmentier-Batteur et al., 2014), VU0409551 did not induce behavioral convulsions after repeated once-daily administration of high doses (450 mg/kg) over 14 days (data not shown). Thus, VU0409551 does not have detectable toxic effects at the doses well above those used for these behavioral studies.
DISCUSSION
Converging evidence suggests that NMDAR hypofunction is a primary risk factor for schizophrenia (Coyle et al., 2012; Field et al., 2011; Matosin and Newell, 2013; Timms et al., 2013) . NMDAR and mGlu 5 are co-localized at postsynaptic sites implicated in the pathology of schizophrenia and their intracellular domains are physically connected via scaffold proteins (Gao Hu et al., 2012; Matosin and Newell, 2013; Park et al., 2013; Shepherd and Huganir, 2007) , facilitating the potentiation of NMDAR activity by mGlu 5 activation (Ayala et al., 2009; Homayoun et al., 2004; Mannaioni et al., 2001; Marino and Conn, 2002 ). Numerous reports demonstrate that selective mGlu 5 PAMs have efficacy in animal models of psychosis and cognition (Darrah et al., 2008; Gastambide et al., 2013; Gregory et al., 2013a; Kinney et al., 2003; Liu et al., 2008; Noetzel et al., 2012; Rodriguez et al., 2010) , and these effects have been hypothesized to result from direct potentiation of NMDAR currents. In support of this hypothesis, previous studies revealed that mGlu 5 PAMs potentiate mGlu 5 modulation of NMDAR currents in pyramidal cells of the hippocampus (O'Brien et al., 2004) , and we now confirm these previous findings using multiple, structurally unrelated mGlu 5 PAMs. However, potentiation of mGlu 5 coupling to G aq in postsynaptic neurons also facilitates activity in these forebrain circuits through effector systems independent of NMDAR activation. Discovery of VU0409551 as a potent mGlu 5 PAM that displays signaling bias and does not potentiate mGlu 5 coupling to NMDAR currents while exhibiting robust in vivo efficacy in rodent models provides an exciting advance in our understanding of mGlu 5 pharmacology and suggests that mGlu 5 acts in concert with NMDARs to modulate brain circuits that are impacted in these models rather than exerting actions that are fully dependent on mGlu 5 modulation of NMDAR signaling.
While these data are consistent with a clear stimulus bias and lack of effect of VU0409551 on mGlu 5 modulation of NMDAR currents, it is important to note that VU0409551 could cause an indirect potentiation of NMDAR function in some neuronal populations by depolarizing neurons, reducing the voltagedependent Mg 2+ block of NMDAR channels and thereby increase NMDAR currents indirectly. However, DHPG-induced depolarization of pyramidal cells in hippocampal area CA1 in rats is mediated by mGlu 1 rather than mGlu 5 (Mannaioni et al., 2001) . Thus, selective potentiation of mGlu 5 is not likely to potentiate NMDAR function by depolarizing the pyramidal cells at this particular synapse. However, mGlu 5 activation inhibits the slow AHP current (I AHP ) and thereby increases excitability in CA1 pyramidal cells (Mannaioni et al., 2001) . Thus, the overall physiological effects of mGlu 5 activation in forebrain circuits include multiple actions that are independent of direct modulation of NMDAR currents but act in concert with NMDAR signaling to enhance transmission through circuits that are impacted in schizophrenia and relevant animal models. This and other mechanisms by which mGlu 5 activation can enhance transmission at synapses where NMDARs play important roles would likely enhance transmission through these circuits and may be involved in the efficacy of mGlu 5 PAMs. Similar to previously reported mGlu 5 PAMs, VU0409551 exhibits selective, potent potentiation of mGlu 5 -mediated calcium mobilization. Importantly, VU0409551 does not possess intrinsic allosteric agonist activity in induction of calcium mobilization in cell-based assays or native systems but potentiates glutamateinduced increases in intracellular calcium, therefore displaying pure PAM activity at mGlu 5 in this assay. Previous studies suggest that allosteric agonist or ''ago-PAM'' activity in inducing calcium mobilization is a primary factor that can contribute to adverse effects of mGlu 5 PAMs (Conn et al., 2014; Rook et al., 2013) . Thus, the lack of ago-PAM activity in VU0409551 in this assay is a critical property for avoiding adverse effects. However, mGlu 5 PAMs that lack allosteric agonist activity can still lead to seizures and cell death after chronic administration of high doses (Parmentier-Batteur et al., 2014) . This, coupled with the established role of NMDAR activation in excitotoxicity throughout the CNS (Stone and Burton, 1988) , raises the possibility that agents that do not potentiate mGlu 5 modulation of NMDAR currents could provide the desired efficacy while reducing the risk of neurotoxic effects. Thus, the stimulus bias provided by VU0409551 that allows potentiation of mGlu 5 signaling through G aq without potentiation of mGlu 5 coupling to NMDAR current modulation could be a significant factor that leads to the improved safety profile that we observe for this novel mGlu 5 PAM, in which no toxicity is observed in the dose range that provides preclinical efficacy in rats. However, it is important to note that there can be species differences in the PAM-induced activation of specific signaling cascades (Conn et al., 2014; Croy et al., 2014) or pharmacokinetic differences across species, all of which may affect their net in vivo effects. Thus, this type of stimulus bias can be species dependent and we cannot extrapolate beyond the current studies to make predictions regarding effects of VU0409551 on NMDAR currents and likely safety of this compound in other species. Indeed, when administered chronically at very high doses (360 mg/kg, once daily for 1 month), we have found evidence that VU0409551 can induce FJC staining (P.J.C., unpublished data). A) VU0409551 (10-100 mg/kg) reverses MK-801-induced hyperlocomotion in rats with a minimum effective dose of 10 mg/kg and maximum reversal of 49.7% at 100 mg/kg. Data are expressed as the mean total number of beam breaks per 5 min intervals ± SEM. Area under the curve from time interval t = 60 to 120 min was quantified for each treatment group and expressed as total ambulations. Percent reversal was calculated after normalizing to the vehicle + MK-801 treatment group (p < 0.0001, n = 10-12). (B) VU0409551 dose-dependently enhances acquisition of contextual fear conditioning in rats. Pretreatment with 1, 3, 5.6, and 10 mg/kg VU0409551 prior to conditioning significantly enhanced acquisition of fear conditioning assessed 24 hr later (p = 0.0005, n = 10-13). Data are expressed as mean ± SEM. ***p < 0.001, **p < 0.01, and *p < 0.05. (C) VU0409551 dose-dependently enhances recognition memory in rats. Pretreatment with 3 and 10 mg/kg VU0409551 prior to exposure to identical objects significantly enhanced recognition memory assessed 24 hr later (p = 0.0014, n = 19). Data are expressed as mean ± SEM. ***p < 0.001 and *p < 0.05. (D) VU0409551 demonstrates pro-cognitive effects in the delayed non-matching to position task in rats. Pretreatment with VU0409551 (10-60 mg/kg) prior to testing significantly increased the proportion of correct responses at 10 s and 20 s delays, respectively (p = 0.0236, n = 15-35). Data are expressed as mean ± SEM. *p < 0.05.
It was especially interesting to find that VU0409551 does not potentiate TBS-induced LTP in the hippocampus. This is in contrast to previous mGlu 5 PAMs, which induce robust potentiation of TBS-LTP (Ayala et al., 2009; Noetzel et al., 2013) . Induction of LTP at this synapse is known to be NMDAR dependent (Ben-Ari et al., 1992; Harris et al., 1984; Mü ller et al., 2013) . Thus, this finding, together with the lack of ability of VU0409551 to potentiate mGlu 5 modulation of NMDAR currents, is consistent with the hypothesis that mGlu 5 -induced potentiation of hippocampal LTP is dependent on the ability of mGlu 5 to potentiate NMDAR currents (Ben-Ari et al., 1992; Collingridge et al., 2013; Mannaioni et al., 2001) . Interestingly, VU0409551 did enhance fear conditioning and novel object recognition, which are established models of hippocampal-dependent cognitive function (Franç a et al., 2014; Maren and Holt, 2000) . VU0409551 also improved performance in an operant DNMTP task, which assesses cortical-dependent working memory and executive function. These data suggest that the cognition-enhancing effects of mGlu 5 PAMs in are not dependent upon potentiation of NMDAR currents or LTP. However, as mentioned above, mGlu 5 activation has a broad range of effects in the hippocampus and cortical circuits that are unrelated to modulation of NMDAR currents but increase overall transmission through the hippocampal circuit. In the future, it will be important to perform further studies to better understand the mechanisms by which mGlu 5 PAMs enhance cognitive function.
EXPERIMENTAL PROCEDURES
In Vitro Assays Cell Culture and In Vitro Assays HEK293A cells stably expressing rat mGlu 5 or mGlu 1 and primary rat cortical astrocytes (Lonza) were maintained and measurement of mGlu 5 -or mGlu 1 -mediated intracellular Ca 2+ mobilization was performed as previously described (Hammond et al., 2010; Rodriguez et al., 2010; Rook et al., 2013) . For selectivity screening, calcium flux in HEK293 cells stably expressing rat mGlu 1 or thallium flux through GIRK channels in HEK293-GIRK cells expressing mGlu subtype 2, 3, 4, 6, 7, or 8 was measured as described in Supplemental Experimental Procedures (Hammond et al., 2010; Niswender et al., 2008; Rodriguez et al., 2010) . Measurement of mGlu 5 -mediated ERK phosphorylation was performed in HEK293A cells stably expressing rat mGlu 5 using the ALPHAScreen-based ERK Surefire kit (Perkin-Elmer, TGR Biosciences) as described in Supplemental Experimental Procedures and previously (Gregory et al., 2012) .
In Vivo Studies Animals All present studies used male Sprague Dawley (SD) rats (Harlan) with the exception of the delayed non-matching to position task (male Lister-hooded rats [Harlan] ), which were cared for in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All experimental procedures were approved by the Vanderbilt University Animal Care and Use Committee. Unless otherwise stated, all VU0409551 dosing was performed orally in 20% b-cyclodextrin at 3 ml/kg. Additional detailed methods for animal studies below can be found in the Supplemental Experimental Procedures.
Brain Slice Electrophysiology
Whole-Cell Voltage-and Current-Clamp Recordings Transverse hippocampal slices were prepared from rats (age 17-28 days) (Charles River). Whole-cell recordings were made from hippocampal CA1 pyramidal neuron soma. NMDA receptor-mediated responses were induced by pressure ejection of 0.5-1 mM NMDA to the dendritic field near the soma of the recorded cell every 30 s through a patch pipette using a Picospritzer II (General Valve). This experiment was carried out in the presence of tetrodotoxin (1 mM), and the cell was voltage clamped at À65 to À70 mV or recorded at resting membrane potential under current clamp. For the studies of synaptic NMDAR currents, EPSCs AMPA and EPSCs NMDA were evoked by electrical stimulation of Schaffer collaterals every 30 s and recorded at holding potential of À60 mV and +40 mV, respectively, in the presence of 20 mM bicuculline. All drugs were bath applied. Data were analyzed using Clampfit 10.2, Origin 6 (OriginLab) and Prism 5.0 (GraphPad Software).
Extracellular Field Potential Recordings
Transverse hippocampal slices were prepared from young adult (age 29-36 days) rats (Charles River) (Ayala et al., 2009; Noetzel et al., 2012) . A bipolar-stimulating electrode was utilized to stimulate the Schaffer collaterals and field potential recordings were acquired from the CA1. mGlu 5 compounds were applied to the bath for 10-20 min and chemically induced mGlu LTD was initiated by the application of DHPG for 10 min. Threshold LTP was induced by one train of theta burst stimulation (TBS; nine bursts of four pluses at 100 Hz, 230-ms interburst interval). Saturated LTP was induced by four trains of 10 Hz TBS (nine bursts of four pulses at 100 Hz, 100-ms interburst interval). Data were analyzed using Clampfit 10.2 and GraphPad Prism 5.0 .
Drug Metabolism and Pharmacokinetics in Rat
The in vitro and in vivo rat drug metabolism and pharmacokinetic properties of VU0409551 were determined essentially as previously described Gregory et al., 2013a; Jones et al., 2012) . Rat Chronic Dosing Satellite PK for Fluoro-Jade Studies In order to determine the PK of VU0409551 following chronic administration (once daily [QD] for 4 days; 120 mg/kg, p.o., vehicle: 70% PEG 400 in water) to non-fasted rats used in Fluoro-Jade studies, we obtained serial blood samples and plasma concentrations determined at 3, 7, and 24 hr post-administration on day 1 and day 4. Samples and data were analyzed as described above via LC-MS/MS quantification.
Behavioral Studies
Sleep-Wake Electroencephalography Studies Electroencephalography (EEG) and electromyography (EMG) data were recorded from rats (250-275 g) beginning at the start of the light cycle. VU0409551 was then administered (vehicle, 10, or 60 mg/kg) at the second hour of the light period. Sleep polygraphic variables were measured for a period of 22 hr after compound administration in rats. EEG and EMG waveform data were collected using Dataquest A.R.T. 4.3 software (DSI) using a continuous sampling method. Telemetric data were sampled at a rate of 500 Hz and transmitted via a receiver (RPC-2, DSI, MN) placed below the cage of each rat. Data were scored manually by a blinded observer into 10 s epoch using Neuroscore 3.0 software (Data Sciences International) to determine changes in sleep-wake stages following dosing based upon accepted characteristic oscillatory patterns. Sleep-wake stages were scored in 10 s epochs then NREM and REM sleep time was combined into 60 min bins to examine the percent of time spent in total sleep across the first 22 hr cycle following compound administration. MK-801-Induced Hyperlocomotion Effects of VU0409551 on MK-801-induced hyperlocomotion in rats were determined using an open-field chamber (KinderScientific). At t = 30, rats were administered vehicle or VU0409551 (10-100 mg/ kg) followed by MK-801 (0.2 mg/kg, s.c., saline, 1 ml/kg) at t = 60 min. Locomotor activity was measured for an additional 60 min. Changes in locomotor activity were measured as the total number of photobeam breaks per 5 min bins.
Contextual Fear Conditioning
Effects of VU0409551 on acquisition of contextual fear conditioning were evaluated in rats (275-300 g) (Lebois et al., 2010) . Rats were given a 30 min pretreatment of VU0409551 (0.3-10 mg/kg) and placed in a sound-attenuating conditioning chamber (Med Associates) in the presence of 1 ml of a 10% vanilla extract solution. Following a 2 min habituation period, rats received a one shock-context pairing trials (1 s, 0.5 mA) and after 45 s were returned to their home cages. Twenty-four hours later, the fear response was assessed in the same conditioning environment for 2 min 45 s, measuring freezing behavior in the absence of any shock stimuli or drug. Testing sessions were recorded and time spent freezing was scored by blinded personnel (MED-VFC-RS, MedAssociates). Novel Object Recognition Effects of VU0409551 on recognition memory were evaluated in rats (275-300 g). Rats were habituated in an empty novel object recognition (NOR) arena for 10 min for 2 consecutive days. On day 3, rats were administered vehicle, 1, 3, or 10 mg/kg of VU0409551 30 min before being placed into the NOR arena containing two identical objects. Following a 10 min exposure period, rats were placed back into their home cages, and 24 hr later returned to the arena in which one of the previously exposed (familiar) objects was replaced by a novel object. The rats were video recorded for 10 min while they explored the objects. Time spent exploring each object was scored by a blinded observer.
Delayed Non-Matching to Position Effects of VU0409551 on working memory and executive function were evaluated in the delayed non-matching to position (DNMTP) task using male Lister-hooded rats (350-450 g). Rats were trained to ensure a high level of stable and accurate performance was obtained. Rats were administered vehicle or VU0409551 (10-60 mg/kg) 60 min prior to testing. Four delay lengths (1, 10, 20, and 30 s) were used in this study with 15 trials occurring at each delay (60 trials total). Rats were allowed a maximum of 45 min to complete these trials.
Fluoro-Jade C Staining Twenty-four hours after the last dose of VU0409551 or VU0424465, Fluorojade C staining was performed on rat brains. Fluoro-jade C-positive neurons within the auditory cortex were counted under 203 magnification. A total of five sections per animal was quantified and the data are presented as mean number of cells per section. 
